Search Results
10
Everything
Search Filters
Organization
Recursion Pharmaceuticals
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
March 18, 2025 08:00 ET
|
Recursion Pharmaceuticals
Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
February 28, 2025 06:30 ET
|
Recursion Pharmaceuticals
Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous...
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
February 24, 2025 08:00 ET
|
Recursion Pharmaceuticals
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will...
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
February 19, 2025 09:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Altitude Lab, a biotech accelerator started by Recursion in Salt Lake City, today announced the launch of its pre-seed venture fund aimed at...
Altitude Lab Startups Raise $154M in Capital
February 18, 2025 11:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020....
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
January 07, 2025 09:15 ET
|
Recursion Pharmaceuticals
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539, a...
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
January 06, 2025 08:30 ET
|
Recursion Pharmaceuticals
Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder...
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
December 20, 2024 16:05 ET
|
Recursion Pharmaceuticals
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion and Exscientia Shareholders Approve the Proposed Combination
November 13, 2024 09:08 ET
|
Recursion Pharmaceuticals
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the...
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
November 06, 2024 16:15 ET
|
Recursion Pharmaceuticals
Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and...